Zum Inhalt

HealthOSArzneimittel

HealthOSEvidence Desk

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (39)

Wechselwirkungen · Harvoni

Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19

HOS-132269 · Präparat HOS-097208

18 Medicinal product by Effects on medicinal Recommendation concerning co-administration therapeutic areas product levels. with Harvoni Mean ratio (90% confidence interval) for AUC, Cmax, Cmina, b ORAL CONTRACEPTIVES Norgestimate/ ethinyl Norelgestromin No dose adjustment of oral contraceptives is estradiol (norgestimate ↔ Cmax 1.02 (0.89, 1.16) required. 0.180 mg/ 0.215 mg/ ↔ AUC 1.03 (0.90, 1.18) 0.25 mg/ ethinyl estradiol ↔ Cmin 1.09 (0.91, 1.31) 0.025 mg)/ ledipasvir (90 mg once daily)d Norgestrel ↔ Cmax 1.03 (0.87, 1.23) ↔ AUC 0.99 (0.82, 1.20) ↔ Cmin 1.00 (0.81, 1.23)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) norelgestromin (HOS-110295) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage fbb7868309e97046cbc7651b2a5be0c5502209a82a83ee38d56a6e3e1eeeffc0 · Zeichen 36924–37896 im Abschnitt

Wechselwirkungen · Harvoni

Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19

HOS-132270 · Präparat HOS-097208

Ethinyl estradiol ↑ Cmax 1.40 (1.18, 1.66) ↔ AUC 1.20 (1.04, 1.39) ↔ Cmin 0.98 (0.79, 1.22) Norgestimate/ ethinyl Norelgestromin estradiol (norgestimate ↔ Cmax 1.07 (0.94, 1.22) 0.180 mg/ 0.215 mg/ ↔ AUC 1.06 (0.92, 1.21) 0.25 mg/ ethinyl estradiol ↔ Cmin 1.07 (0.89, 1.28) 0.025 mg)/ sofosbuvir (400 mg once daily)d Norgestrel ↔ Cmax 1.18 (0.99, 1.41) ↑ AUC 1.19 (0.98, 1.45) ↑ Cmin 1.23 (1.00, 1.51)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) norelgestromin (HOS-110295) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 3eea0df9ea83b2cb76c138378fba10c8e963ca2e2a1554b8737ac6e66b7f872d · Zeichen 37934–38617 im Abschnitt

Wechselwirkungen · Harvoni

Harvoni 33.75 mg/150 mg coated granules in sachet Harvoni 45 mg/200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 57

HOS-132373 · Präparat HOS-097208

GS-331007 ↔ Cmax 0.97 (0.83, 1.14) ↔ AUC 1.00 (0.87, 1.13) ORAL CONTRACEPTIVES Norgestimate/ ethinyl Norelgestromin No dose adjustment of oral contraceptives is estradiol (norgestimate ↔ Cmax 1.02 (0.89, 1.16) required. 0.180 mg/ 0.215 mg/ ↔ AUC 1.03 (0.90, 1.18) 0.25 mg/ ethinyl estradiol ↔ Cmin 1.09 (0.91, 1.31) 0.025 mg)/ ledipasvir (90 mg once daily)d Norgestrel ↔ Cmax 1.03 (0.87, 1.23) ↔ AUC 0.99 (0.82, 1.20) ↔ Cmin 1.00 (0.81, 1.23)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) norelgestromin (HOS-110295) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage c29c4afb9ced4bcb1e41fe390fc959f6c9c3ed1c6e0c3445ee07d571e347f458 · Zeichen 37120–37803 im Abschnitt

Wechselwirkungen · Harvoni

Harvoni 33.75 mg/150 mg coated granules in sachet Harvoni 45 mg/200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 57

HOS-132374 · Präparat HOS-097208

Ethinyl estradiol ↑ Cmax 1.40 (1.18, 1.66) ↔ AUC 1.20 (1.04, 1.39) ↔ Cmin 0.98 (0.79, 1.22) Norgestimate/ ethinyl Norelgestromin estradiol (norgestimate ↔ Cmax 1.07 (0.94, 1.22) 0.180 mg/ 0.215 mg/ ↔ AUC 1.06 (0.92, 1.21) 0.25 mg/ ethinyl estradiol ↔ Cmin 1.07 (0.89, 1.28) 0.025 mg)/ sofosbuvir (400 mg once daily)d Norgestrel ↔ Cmax 1.18 (0.99, 1.41) ↑ AUC 1.19 (0.98, 1.45) ↑ Cmin 1.23 (1.00, 1.51)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) norelgestromin (HOS-110295) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 6ae8f416f321ebf156cd30d54ca92bc240683b95688892a3085b95c31c5dfb3d · Zeichen 37838–38488 im Abschnitt

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16

HOS-133994 · Präparat HOS-097520

Elvitegravir: AUC: ↔ Cmin: ↔ Cmax: ↔ ORAL CONTRACEPTIVES Drospirenone/Ethinyloestradiol Interaction not studied with Plasma concentrations of (3 mg/0.02 mg single dose)/ Genvoya. drospirenone may be increased Cobicistat (150 mg once daily) when co-administered with Expected cobicistat-containing products. Drospirenone: Clinical monitoring is recommended AUC: ↑ due to the potential for hyperkalaemia. Norgestimate Norelgestromin: (0.180/0.215/0.250 mg once daily)/ AUC: ↔ Caution should be exercised when Ethinyloestradiol (0.025 mg once Cmin: ↔ co-administering Genvoya and a daily)/ Emtricitabine/Tenofovir Cmax: ↔ hormonal contraceptive. The alafenamide (200/25 mg once hormonal contraceptive should daily)6 Norgestrel: contain at least 30 µg AUC: ↔ ethinyloestradiol and contain Cmin: ↔ drospirenone or norgestimate as the Cmax: ↔ progestogen or patients should use an alternative reliable method of Ethinyloestradiol: contraception (see sections 4.4 and AUC: ↔ 4.6). Cmin: ↔ Cmax: ↔ The long-term effects of substantial increases in progestogen exposure are unknown. Norgestimate (0.180/0.215 mg Norgestimate: once daily)/ Ethinyloestradiol AUC: ↑ 126% (0.025 mg once daily)/ Elvitegravir Cmin: ↑ 167% (150 mg once daily)/ Cobicistat Cmax: ↑ 108% (150 mg once daily)4 Ethinyloestradiol: AUC: ↓ 25% Cmin: ↓ 44% Cmax: ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) norgestimate (HOS-110544) norelgestromin (HOS-110295) drospirenone (HOS-116422) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 1ae6d00b57eca6358408c9d03216ad76a272600421ad5e213a7578bcf03caaf0 · Zeichen 29066–31848 im Abschnitt

Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Mylan

Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26–27

HOS-134279 · Präparat HOS-097542

26 Medicinal product by Effects on drug Recommendation concerning therapeutic areas levels co-administration with Mean percent emtricitabine/tenofovir disoproxil change in AUC, (emtricitabine 200 mg, tenofovir disoproxil Cmax, Cmin with 245 mg) 90% confidence intervals if available (mechanism) ORAL CONTRACEPTIVES Norgestimate/Ethinyl oestradiol Norgestimate: No dose adjustment of norgestimate/ethinyl /Tenofovir disoproxil AUC: ↓ 4% (↓ 32 to oestradiol is required. ↑ 34) Cmax: ↓ 5% (↓ 27 to ↑ 24) Cmin: NC

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) tenofovir disoproxil (HOS-108843)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-03T14:25:00Z · SHA-256 dca28001b5f37f5fac24ef504bb45938e413f238844fb60b012f3f9b5a32b40c · Passage 59962102c7108e72e7457ed9b1c18334cd8cb0ee28cb88a28aa6aecaf847a4a7 · Zeichen 46077–47271 im Abschnitt

Wechselwirkungen · Descovy

Descovy 200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12

HOS-134974 · Präparat HOS-097638

Co-administration of ciclosporin, a potent P-gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide. ORAL CONTRACEPTIVES Norgestimate Norelgestromin: No dose adjustment of (0.180/0.215/0.250 mg once AUC: ↔ norgestimate/ethinylestradiol is daily), ethinylestradiol (0.025 mg Cmin: ↔ required. Dose Descovy according once daily), Cmax: ↔ to the concomitant antiretroviral emtricitabine/tenofovir (see section 4.2). alafenamide (200/25 mg once Norgestrel: daily)5 AUC: ↔ Cmin: ↔ Cmax: ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) norgestimate (HOS-110544) norelgestromin (HOS-110295) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage 1959160ff82a387bdefed7d06c10a39dd8a6543da83281ec6ec534c3776f3b29 · Zeichen 21113–22122 im Abschnitt

Wechselwirkungen · Descovy

Descovy 200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 38

HOS-135042 · Präparat HOS-097638

Co-administration of ciclosporin, a potent P-gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide. ORAL CONTRACEPTIVES Norgestimate Norelgestromin: No dose adjustment of (0.180/0.215/0.250 mg once AUC: ↔ norgestimate/ethinylestradiol is daily), ethinylestradiol (0.025 mg Cmin: ↔ required. Dose Descovy according once daily), Cmax: ↔ to the concomitant antiretroviral emtricitabine/tenofovir (see section 4.2). alafenamide (200/25 mg once Norgestrel: daily)5 AUC: ↔ Cmin: ↔ Cmax: ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) norgestimate (HOS-110544) norelgestromin (HOS-110295) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage 1959160ff82a387bdefed7d06c10a39dd8a6543da83281ec6ec534c3776f3b29 · Zeichen 21117–22126 im Abschnitt

Wechselwirkungen · Vemlidy

Vemlidy 25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 10

HOS-135938 · Präparat HOS-097792

Rilpivirine ↔ Cmax 0.93 (0.87, 0.99) ↔ AUC 1.01 (0.96, 1.06) ↔ Cmin 1.13 (1.04, 1.23) HIV ANTIRETROVIRAL AGENTS – CCR5 RECEPTOR ANTAGONIST Maraviroc Interaction not studied. No dose adjustment of Vemlidy or maraviroc is Expected: required. ↔ Tenofovir alafenamide ↔ Maraviroc HERBAL SUPPLEMENTS St. John’s wort (Hypericum Interaction not studied. Co-administration is not recommended. perforatum) Expected: ↓ Tenofovir alafenamide ORAL CONTRACEPTIVES Norgestimate Norelgestromin No dose adjustment of Vemlidy or (0.180 mg/0.215 mg/ ↔ Cmax 1.17 (1.07, 1.26) norgestimate/ethinyl estradiol is required. 0.250 mg orally, q.d.) ↔ AUC 1.12 (1.07, 1.17) ↔ Cmin 1.16 (1.08, 1.24) Ethinylestradiol (0.025 mg orally, q.d.) Norgestrel ↔ Cmax 1.10 (1.02, 1.18) Tenofovir alafenamidec ↔ AUC 1.09 (1.01, 1.18) (25 mg orally, q.d.) ↔ Cmin 1.11 (1.03, 1.20)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) norgestimate (HOS-110544) norelgestromin (HOS-110295) ethinyl estradiol (HOS-088135) maraviroc (HOS-086186) rilpivirine (HOS-088090) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2023-05-31T09:05:00Z · SHA-256 fe69ec0120bf519ffbfbc733bef6aef6622c9f34191c9918790e7ff2aa064333 · Passage 5a0c311534aceb1618c6f97c500f9e7093f6e3de204711dd10f2793eeb44828b · Zeichen 14279–15459 im Abschnitt

Wechselwirkungen · Epclusa

Epclusa 400 mg/100 mg film-coated tablets Epclusa 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14

HOS-136151 · Präparat HOS-097846

13 Medicinal product by Effects on medicinal product levels. therapeutic areas/Possible Mean ratio (90% confidence interval)a,b Recommendation concerning Mechanism of Interaction Active Cmax AUC Cmin co-administration with Epclusa IMMUNOSUPPRESSANTS Ciclosporin Ciclosporin ↔ ↔ No dose adjustment of Epclusa or (600 mg single dose)/ ciclosporin is required at initiation sofosbuvir (400 mg single Sofosbuvir ↑ ↑ of co-administration. Afterwards, dose)f 2.5 4.5 close monitoring and potential (1.9, (3.3, dose adjustment of ciclosporin may 3.5) 6.3) be required. Ciclosporin Ciclosporin ↔ ↓ (600 mg single dose)f/ 0.88 velpatasvir (100 mg single (0.78, dose)d 1.0) Velpatasvir ↑ ↑ 1.6 2.0 (1.2, (1.5, 2.0) 2.7) Tacrolimus Tacrolimus ↓ ↑ No dose adjustment of Epclusa or (5 mg single dose)f/ 0.73 1.1 tacrolimus is required at initiation sofosbuvir (400 mg single (0.59, (0.84, of co-administration. Afterwards, dose)d 0.90) 1.4) close monitoring and potential Sofosbuvir ↓ ↑ dose adjustment of tacrolimus may 0.97 1.1 be required. (0.65, (0.81, 1.4) 1.6) Tacrolimus Effect on velpatasvir exposure not studied. Expected: ↔ Velpatasvir ORAL CONTRACEPTIVES Norgestimate/ ethinyl Norel- ↔ ↔ ↔ No dose adjustment of oral estradiol (norgestimate gestromin contraceptives is required. 0.180 mg/ 0.215 mg/ 0.25 mg/ ethinyl estradiol 0.025 mg)/ sofosbuvir (400 mg once daily)d Norgestrel ↔ ↑ ↑ 1.2 1.2 (0.98, (1.0, 1.5) 1.5) Ethinyl ↔ ↔ ↔ estradiol Norgestimate/ ethinyl Norel- ↔ ↔ ↔ estradiol (norgestimate gestromin 0.180 mg/ 0.215 mg/ Norgestrel ↔ ↔ ↔ 0.25 mg/ ethinyl estradiol 0.025 mg)/ velpatasvir Ethinyl ↑ ↔ ↓ (100 mg once daily)d estradiol 1.4 0.83 (1.2, (0.65, 1.7) 1.1) a Mean ratio (90% CI) of co-administered drug pharmacokinetics of study medicinal products alone or in combination. No effect = 1.00. b All interaction studies conducted in healthy volunteers. c Administered as Epclusa. d Lack of pharmacokinetics interaction bounds 70-143%. e These are medicinal products within class where similar interactions could be predicted. f Bioequivalence/Equivalence boundary 80-125%. g Lack of pharmacokinetics interaction bounds 50-200%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) tacrolimus (HOS-085202) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 45c83336337cae9db449bdcbc491a9e681d695046d8d754f5f2c8d614b0118af · Zeichen 28975–33232 im Abschnitt

Wechselwirkungen · Epclusa

Epclusa 200 mg/50 mg coated granules in sachet Epclusa 150 mg/37.5 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 45–46

HOS-136199 · Präparat HOS-097846

45 Medicinal product by Effects on medicinal product levels. therapeutic areas/Possible Mean ratio (90% confidence interval)a,b Recommendation concerning Mechanism of Interaction Active Cmax AUC Cmin co-administration with Epclusa ORAL CONTRACEPTIVES Norgestimate/ ethinyl Norel- ↔ ↔ ↔ No dose adjustment of oral estradiol (norgestimate gestromin contraceptives is required. 0.180 mg/ 0.215 mg/ 0.25 mg/ ethinyl estradiol 0.025 mg)/ sofosbuvir (400 mg once daily)d Norgestrel ↔ ↑ ↑ 1.2 1.2 (0.98, (1.0, 1.5) 1.5) Ethinyl ↔ ↔ ↔ estradiol Norgestimate/ ethinyl Norel- ↔ ↔ ↔ estradiol (norgestimate gestromin 0.180 mg/ 0.215 mg/ Norgestrel ↔ ↔ ↔ 0.25 mg/ ethinyl estradiol 0.025 mg)/ velpatasvir Ethinyl ↑ ↔ ↓ (100 mg once daily)d estradiol 1.4 0.83 (1.2, (0.65, 1.7) 1.1) a Mean ratio (90% CI) of co-administered drug pharmacokinetics of study medicinal products alone or in combination. No effect = 1.00. b All interaction studies conducted in healthy volunteers. c Administered as Epclusa. d Lack of pharmacokinetics interaction bounds 70-143%. e These are medicinal products within class where similar interactions could be predicted. f Bioequivalence/Equivalence boundary 80-125%. g Lack of pharmacokinetics interaction bounds 50-200%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 16bc5665617bc06d787fceb05d3567a1ecf4555368f610a2b4fe92aabbbec5bc · Zeichen 30857–32980 im Abschnitt

Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka

Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19

HOS-136611 · Präparat HOS-097888

18 Herpes virus antiviral agents Famciclovir/Emtricitabine Famciclovir: No dose adjustment of famciclovir is AUC: ↓ 9% (↓ 16 to ↓ 1) required. Cmax: ↓ 7% (↓ 22 to ↑ 11) Cmin: NC Emtricitabine: AUC: ↓ 7% (↓ 13 to ↓ 1) Cmax: ↓ 11% (↓ 20 to ↑ 1) Cmin: NC Antimycobacterials Rifampicin/Tenofovir disoproxil Tenofovir: No dose adjustment is required. AUC: ↓ 12% (↓ 16 to ↓ 8) Cmax: ↓ 16% (↓ 22 to ↓ 10) Cmin: ↓ 15% (↓ 12 to ↓ 9) ORAL CONTRACEPTIVES Norgestimate/Ethinyl Norgestimate: No dose adjustment of oestradiol/Tenofovir disoproxil AUC: ↓ 4% (↓ 32 to ↑ 34) norgestimate/ethinyl oestradiol is Cmax: ↓ 5% (↓ 27 to ↑ 24) required. Cmin: NC Ethinyl oestradiol: AUC: ↓ 4% (↓ 9 to ↑ 0) Cmax: ↓ 6% (↓ 13 to ↑ 0) Cmin: ↓ 2% (↓ 9 to ↑ 6) IMMUNOSUPPRESSANTS Tacrolimus/Tenofovir disoproxil Tacrolimus: No dose adjustment of tacrolimus is /Emtricitabine AUC: ↑ 4% (↓ 3 to ↑ 11) required. Cmax: ↑ 3% (↓ 3 to ↑ 9) Cmin: NC Emtricitabine: AUC: ↓ 5% (↓ 9 to ↓ 1) Cmax: ↓ 11% (↓ 17 to ↓ 5) Cmin: NC Tenofovir: AUC: ↑ 6% (↓ 1 to ↑ 13) Cmax: ↑13% (↑ 1 to ↑ 27) Cmin: NC NARCOTIC ANALGESICS Methadone/Tenofovir disoproxil Methadone: No dose adjustment of methadone is AUC: ↑ 5% (↓ 2 to ↑ 13) required. Cmax: ↑ 5% (↓ 3 to ↑ 14) Cmin: NC NC = not calculated. N/A = not applicable. 1 Data generated from simultaneous dosing with ledipasvir/sofosbuvir. Staggered administration (12 hours apart) provided similar results. 2 The predominant circulating metabolite of sofosbuvir. 3 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famciclovir (HOS-112681) tenofovir (HOS-088083) sofosbuvir (HOS-108928) norgestimate (HOS-110544) methadone (HOS-086198) ledipasvir (HOS-110493) voxilaprevir (HOS-108930) tacrolimus (HOS-085202)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-01-31T12:47:00Z · SHA-256 bff22a935481266901d4c92f1163f09cb1d50edd80ede33ac1750318fed62b8d · Passage 1165540b4250a3c5ce2fbcaaf9521c181859e9036c79ca035072976a797446f7 · Zeichen 33912–36969 im Abschnitt

Wechselwirkungen · Maviret

Maviret 100 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–8

HOS-139037 · Präparat HOS-098268

6 ANTIMYCOBACTERIALS Rifampicin ↑ glecaprevir 6.52 8.55 Co-administration 600 mg single (5.06, 8.41) (7.01, -- is contraindicated dose 10.4) (see section 4.3). ↔ ↔ ↔ -- (Inhibition of pibrentasvir OATP1B1/3) Rifampicin ↓ glecaprevir 0.14 0.12 -- 600 mg once (0.11, 0.19) (0.09, dailya 0.15) ↓ pibrentasvir 0.17 0.13 -- (Induction of P- (0.14, 0.20) (0.11, gp/BCRP/CYP3A 0.15) ) ETHINYL-OESTRADIOL-CONTAINING PRODUCTS Ethinyloestradiol ↑ EE 1.31 1.28 1.38 Co-administration (EE)/Norgestimate (1.24, 1.38) (1.23, (1.25, 1.52) of Maviret with 35 µg/250 µg once 1.32) ethinyloestradiol- daily ↑ ↔ 1.44 1.45 containing norelgestromi (1.34, (1.33, 1.58) products is n 1.54) contraindicated ↑ norgestrel 1.54 1.63 1.75 due to the risk of (1.34, 1.76) (1.50, (1.62, 1.89) ALT elevations 1.76) (see section 4.3). EE/Levonorgestrel ↑ EE 1.30 1.40 1.56 No dose 20 µg/100 µg once (1.18, 1.44) (1.33, (1.41, 1.72) adjustment is daily 1.48) required with ↑ norgestrel 1.37 1.68 1.77 levonorgestrel, (1.23, 1.52) (1.57, (1.58, 1.98) norethidrone or 1.80) norgestimate as contraceptive progestagen. HERBAL PRODUCTS St. John’s wort Not studied. Co-administration (Hypericum Expected: ↓ glecaprevir and ↓ pibrentasvir may lead to perforatum) reduced therapeutic effect (Induction of P- of Maviret and is gp/CYP3A) contraindicated (see section 4.3). HIV-ANTIVIRAL AGENTS Atazanavir + ↑ glecaprevir ≥4.06 ≥6.53 ≥14.3 Co-administration ritonavir (3.15, 5.23) (5.24, (9.85, 20.7) with atazanavir is 300/100 mg once 8.14) contraindicated dailyb ↑ pibrentasvir ≥1.29 ≥1.64 ≥2.29 due to the risk of (1.15, 1.45) (1.48, (1.95, 2.68) ALT elevations 1.82) (see section 4.3). Darunavir + ↑ glecaprevir 3.09 4.97 8.24 Co-administration ritonavir (2.26, 4.20) (3.62, (4.40, 15.4) with darunavir is 800/100 mg once 6.84) not daily ↔ ↔ ↔ 1.66 recommended. pibrentasvir (1.25, 2.21) Efavirenz/emtricit ↑ tenofovir ↔ 1.29 1.38 Co-administration abine/tenofovir (1.23, (1.31, 1.46) with efavirenz disoproxil 1.35) may lead to fumarate The effect of efavirenz/emtricitabine/tenofovir disoproxil reduced fumarate on glecaprevir and pibrentasvir was not directly therapeutic effect 7 600/200/300 mg quantified within this study, but glecaprevir and of Maviret and is once daily pibrentasvir exposures were significantly lower than not historical controls. recommended. No clinically significant interactions are expected with tenofovir disoproxil fumarate. Elvitegravir/cobici ↔ tenofovir ↔ ↔ ↔ No dose stat/emtricitabine/ ↑ glecaprevir 2.50 3.05 4.58 adjustment is tenofovir (2.08, 3.00) (2.55, (3.15, 6.65) required. alafenamide 3.64) ↑ pibrentasvir ↔ 1.57 1.89 (P-gp, BCRP, and (1.39, (1.63, 2.19) OATP inhibition 1.76) by cobicistat, OATP inhibition by elvitegravir) Lopinavir/ritonavi ↑ glecaprevir 2.55 4.38 Co-administration 18.6 r 400/100 mg (1.84, 3.52) (3.02, is not (10.4, 33.5) twice daily 6.36) recommended. ↑ pibrentasvir 1.40 2.46 5.24 (1.17, 1.67) (2.07, (4.18, 6.58) 2.92) Raltegravir ↑ raltegravir 1.34 1.47 2.64 No dose 400 mg twice (0.89, 1.98) (1.15, (1.42, 4.91) adjustment is daily 1.87) required.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) norgestimate (HOS-110544) levonorgestrel (HOS-089677) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) lead (HOS-085592) fumarate (HOS-108845) darunavir (HOS-086181) efavirenz (HOS-087947) raltegravir (HOS-086187) ritonavir (HOS-084521) elvitegravir (HOS-088110) emtricitabine (HOS-085840) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 501d3b86f4f9bf1ada9d5743f79220eba7974a639e66758b3eabdbd6816e7dde · Zeichen 6531–13818 im Abschnitt

Wechselwirkungen · Maviret

Maviret 50 mg/20 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 33

HOS-139090 · Präparat HOS-098268

ANTIMYCOBACTERIALS Rifampicin ↑ 6.52 8.55 Co-administration is 600 mg single dose glecaprevir (5.06, 8.41) (7.01, 10.4) -- contraindicated (see ↔ ↔ ↔ -- section 4.3). (Inhibition of pibrentasvir OATP1B1/3) Rifampicin 600 mg ↓ 0.14 0.12 -- once dailya glecaprevir (0.11, 0.19) (0.09, 0.15) ↓ 0.17 0.13 -- (Induction of P- pibrentasvir (0.14, 0.20) (0.11, 0.15) gp/BCRP/CYP3A) ETHINYL-OESTRADIOL-CONTAINING PRODUCTS Ethinyloestradiol ↑ EE 1.31 1.28 1.38 Co-administration of (EE)/Norgestimate (1.24, 1.38) (1.23, 1.32) (1.25, 1.52) Maviret with 35 µg/250 µg once ↑ ↔ 1.44 1.45 ethinyloestradiol- daily norelgestro (1.34, 1.54) (1.33, 1.58) containing products min is contraindicated ↑ norgestrel 1.54 1.63 1.75 due to the risk of (1.34, 1.76) (1.50, 1.76) (1.62, 1.89) ALT elevations (see EE/Levonorgestrel ↑ EE 1.30 1.40 1.56 section 4.3). 20 µg/100 µg once (1.18, 1.44) (1.33, 1.48) (1.41, 1.72) No dose adjustment daily ↑ norgestrel 1.37 1.68 1.77 is required with (1.23, 1.52) (1.57, 1.80) (1.58, 1.98) levonorgestrel, norethidrone or norgestimate as contraceptive progestagen.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) levonorgestrel (HOS-089677) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 32fe903b3a07b4523c3382a44f86d59f20f7199b7b90750b064f679d0d5f2610 · Zeichen 6161–8330 im Abschnitt

Wechselwirkungen · Aimovig

Aimovig 70 mg solution for injection in pre-filled syringe Aimovig 140 mg solution for injection in pre-filled syringe Aimovig 70 mg solution for injection in pre-filled pen Aimovig 140 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 4

HOS-139246 · Präparat HOS-098306

No effect on exposure of co-administered medicinal products is expected based on the metabolic pathways of monoclonal antibodies. No interaction with oral contraceptives (ethinyl estradiol/norgestimate) or sumatriptan was observed in studies with healthy volunteers.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) sumatriptan (HOS-128726) estradiol (HOS-090751)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-12-01T16:50:00Z · SHA-256 3eca639638392984c39621d5f5973e846e56d13ded09a7d8628d6a71c4e0ca87 · Passage 3e249d89395c22fd088741d1f6d46d4290f41140e83efab41651a1b858a149a4 · Zeichen 0–266 im Abschnitt

Wechselwirkungen · Biktarvy

Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-139306 · Präparat HOS-098314

11 Medicinal product by Effects on medicinal product Recommendation concerning therapeutic areas/possible levels. co-administration with Biktarvy mechanism of interaction Mean percent change in AUC, Cmax, Cmin ORAL ANTI-DIABETICS Metformin (500 mg twice daily), Metformin: No dose adjustment is required Bictegravir/Emtricitabine/ AUC: ↑ 39% upon co-administration in patients Tenofovir alafenamide Cmin: ↑ 36% with normal renal function. Cmax: ↔ (Inhibition of OCT2/MATE1) In patients with moderate renal impairment, close monitoring should be considered when starting co-administration of bictegravir with metformin, due to the increased risk for lactic acidosis in these patients. A dose adjustment of metformin should be considered if required. ORAL CONTRACEPTIVES Norgestimate Norelgestromin: No dose adjustment is required (0.180/0.215/0.250 mg once daily)/ AUC: ↔ upon co-administration. Ethinylestradiol (0.025 mg once Cmin: ↔ daily), Bictegravir1 Cmax: ↔ Norgestimate (0.180/0.215/0.250 mg once daily), Norgestrel: Ethinylestradiol (0.025 mg once AUC: ↔ daily), Emtricitabine/Tenofovir Cmin: ↔ alafenamide4 Cmax: ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) norgestimate (HOS-110544) norelgestromin (HOS-110295) metformin (HOS-091032) norgestrel (HOS-090613)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage 8e3d9ad7bf22891bc0f13f6c5eb07364741f27eb20f1aa204daf14bb9621c8ea · Zeichen 21426–23776 im Abschnitt

Wechselwirkungen · Delstrigo

Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15

HOS-141221 · Präparat HOS-098610

14 Recommendation concerning Medicinal product by Effects on medicinal product levels co-administration with therapeutic area geometric mean ratio (90 % CI)* doravirine/lamivudine/tenofovir disoproxil Interaction not studied with doravirine or doravirine/lamivudine/tenofovir buprenorphine disoproxil. No dose adjustment is required. naloxone Expected: buprenorphine naloxone Oral contraceptives ethinyl oestradiol AUC 0.98 (0.94, 1.03) 0.03 mg ethinyl oestradiol/ Cmax 0.83 (0.80, 0.87) 0.15 mg levonorgestrel SD, No dose adjustment is required. doravirine 100 mg QD levonorgestrel AUC 1.21 (1.14, 1.28) Cmax 0.96 (0.88, 1.05) Interaction not studied with doravirine or doravirine/lamivudine/tenofovir norgestimate/ethinyl disoproxil. No dose adjustment is required. oestradiol Expected: norgestimate/ethinyl oestradiol Psychostimulants Interaction not studied with Co-administration should be doravirine or avoided. If co-administration doravirine/lamivudine/tenofovir cannot be avoided, a 100 mg dose disoproxil. of doravirine should be taken modafinil daily, approximately12 h after the Expected: dose of ↓ doravirine doravirine/lamivudine/tenofovir (Induction of CYP3A) disoproxil. Sedatives/Hypnotics midazolam midazolam (2 mg SD, AUC 0.82 (0.70, 0.97) No dose adjustment is required. doravirine 120 mg QD) Cmax 1.02 (0.81, 1.28) Statins atorvastatin atorvastatin (20 mg SD, AUC 0.98 (0.90, 1.06) No dose adjustment is required. doravirine 100 mg QD) Cmax 0.67 (0.52, 0.85) Interaction not studied with doravirine or doravirine/lamivudine/tenofovir rosuvastatin disoproxil. No dose adjustment is required. simvastatin Expected: rosuvastatin simvastatin = increase, ↓ = decrease, ↔ = no change CI = Confidence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily *AUC0- for single dose, AUC0-24 for once daily.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) norgestimate (HOS-110544) atorvastatin (HOS-086304) modafinil (HOS-090546) levonorgestrel (HOS-089677) simvastatin (HOS-086158) rosuvastatin (HOS-086307) buprenorphine (HOS-086193) naloxone (HOS-109490) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage fd386c60abada3e289b35a3ae442851d5dd03fba7a569852b12e6636361437c2 · Zeichen 30057–34050 im Abschnitt

Wechselwirkungen · Pifeltro

Pifeltro 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-141292 · Präparat HOS-098618

11 Medicinal product by Effects on medicinal product Recommendation concerning therapeutic area levels geometric mean ratio co-administration with (90 % CI)* doravirine Oral contraceptives 0.03 mg ethinyl oestradiol/ ethinyl oestradiol 0.15 mg levonorgestrel SD, AUC 0.98 (0.94, 1.03) doravirine 100 mg QD Cmax 0.83 (0.80, 0.87) No dose adjustment is required. levonorgestrel AUC 1.21 (1.14, 1.28) Cmax 0.96 (0.88, 1.05) Interaction not studied. norgestimate/ethinyl No dose adjustment is required. oestradiol Expected: norgestimate/ethinyl oestradiol Pharmacokinetic enhancers doravirine ritonavir AUC 3.54 (3.04, 4.11) (100 mg BID, Cmax 1.31 (1.17, 1.46) No dose adjustment is required. doravirine 50 mg SD) C24 2.91 (2.33, 3.62) (Inhibition of CYP3A) Interaction not studied.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) levonorgestrel (HOS-089677) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage 455488d9b269197cff4961c8625192abffbc06f17ef4ca1a69f134ab343673f8 · Zeichen 24206–25849 im Abschnitt

Wechselwirkungen · Mounjaro

Mounjaro 2.5 mg solution for injection in pre-filled pen Mounjaro 5 mg solution for injection in pre-filled pen Mounjaro 7.5 mg solution for injection in pre-filled pen Mounjaro 10 mg solution for injection in pre-filled pen Mounjaro 12.5 mg solution for injection in pre-filled pen Mounjaro 15 mg solution for injection in pre-filled pen Mounjaro 2.5 mg solution for injection in vial Mounjaro 5 mg solution for injection in vial Mounjaro 7.5 mg solution for injection in vial Mounjaro 10 mg solution for injection in vial Mounjaro 12.5 mg solution for injection in vial Mounjaro 15 mg solution for injection in vial Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 7

HOS-148163 · Präparat HOS-099850

Administration of a combination oral contraceptive (0.035 mg ethinyl estradiol plus 0.25 mg norgestimate, a prodrug of norelgestromin) in the presence of a single dose of tirzepatide (5 mg) resulted in a reduction of oral contraceptive Cmax and area under the curve (AUC). Ethinyl estradiol Cmax was reduced by 59 % and AUC by 20 % with a delay in tmax of 4 hours. Norelgestromin Cmax was reduced by 55 % and AUC by 23 % with a delay in tmax of 4.5 hours. Norgestimate Cmax was reduced by 66 %, and AUC by 20 % with a delay in tmax of 2.5 hours. This reduction in exposure after a single dose of tirzepatide is not considered clinically relevant. No dose adjustment of oral contraceptives is required.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) norelgestromin (HOS-110295) ethinyl estradiol (HOS-088135)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-21T13:40:00Z · SHA-256 8d75eff2f10bd886e04a9cae39b5a53d6eea8dc5f9d2d23738f4b6def2646875 · Passage 378301f99c3e0543b6892a589c32e7b31abf35e031f95a077c1300455a8a17bc · Zeichen 1526–2227 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.